TITLE

AVI BIOPHARMA BEGINS PHASE II CARDIOVASCULAR CLINICAL STUDY

PUB. DATE
November 2005
SOURCE
Worldwide Biotech;Nov2005, Vol. 17 Issue 11, p7
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
18709781

 

Related Articles

  • A Paclitaxel-Eluting Stent for the Prevention of Coronary Restenosis. Park, Seung-Jung; Shim, Won Heum; Ho, David S.; Raizner, Albert E.; Park, Seong-Wook; Hong, Myeong-Ki; Lee, Cheol Whan; Choi, Donghoon; Jang, Yangsoo; Lam, Ricky; Weissman, Neil J.; Mintz, Gary S. // New England Journal of Medicine;4/17/2003, Vol. 348 Issue 16, p1537 

    Background: Intimal hyperplasia and resulting restenosis limit the efficacy of coronary stenting. We studied a coronary stent coated with the antiproliferative agent paclitaxel as a means of preventing restenosis. Methods: We conducted a multicenter, randomized, controlled, triple-blind study to...

  • Paclitaxel-Eluting Stents: Current Clinical Experience. Grube, Eberhard; Buellesfeld, Lutz // American Journal of Cardiovascular Drugs;2004, Vol. 4 Issue 6, p355 

    In the past few years, drug-eluting stents have emerged as one of the most promising technologies in the field of interventional cardiology. Loaded with antiproliferative and anti-inflammatory agents, these stents have the potential to reduce post-stent-implantation restenosis significantly. In...

  • BSC GETS IDE APPROVAL TO BEGIN TAXUS IV CLINICAL TRIAL.  // Biotech Equipment Update;May2002, p5 

    The article reports that Boston Scientific Corp. has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration to begin its TAXUS IV clinical trial. Boston Scientific acquired worldwide co-exclusive rights from Angiotech to use paclitaxel to coat its...

  • Coronary Artery Disease - Restenosis.  // Current Medical Literature: Interventional Cardiology Monitor;2005, Vol. 12 Issue 1, p15 

    The article reports on the results of the Oral Rapamune to Inhibit Restenosis Trial which recruited 60 patients with de novo coronary lesions treated with bare metal stenting. Treatment of one- or two-vessel disease was allowed. The results of this small study are unconvincing and there was...

  • Drug-Eluting Stents.  // Current Medical Literature: Interventional Cardiology Monitor;2005, Vol. 12 Issue 4, p106 

    The article focuses on various research papers related to drug-eluting stents (DESs). As per one of the research papers mentioned in the article, the DESs are considered to be the gold standard with respect to coronary intervention. In DESs, stenting from "normal-normal" has been advocated as...

  • Drug-Eluting Stents.  // Current Medical Literature: Interventional Cardiology Monitor;2006, Vol. 13 Issue 3, p84 

    The article assesses several studies related to drug-eluting stents. A study dealt with Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery trial in patients with three-vessel coronary artery disease. Another study showed the effectivity of drug-eluting stent...

  • Dexamethasone and Restenosis After Coronary Stent Implantation: New Indication for an Old Drug? Weber, Christian; Kaiser, Axel; Schober, Andreas; Hoffmann, Rainer; Radke, Peter W. // Current Pharmaceutical Design;Feb2004, Vol. 10 Issue 4, p349 

    Restenosis after stent implantation is mainly characterized by an inflammatory response to the procedural injury and an intense fibrocellular response including smooth muscle cell (SMC) proliferation. After angioplasty alone, the restenosis process also involves thrombus formation and negative...

  • Bioabsorbable Coronary Stents -- Are These the Next Big Thing in Coronary Angioplasty? Balla, Sudarshan; Aggarwal, Kul; Nistala, Ravi // Recent Patents on Cardiovascular Drug Discovery;Jun2010, Vol. 5 Issue 2, p86 

    The role of percutaneous coronary intervention (PCI) in the treatment of coronary artery disease has grown at an astronomical pace. Drug eluting stents (DES) offer advantages over bare metal stents (BMS) such as reduction in early in-stent restenosis rates. However, they have disadvantages like...

  • Clinical and Angiographic Outcomes of Diabetic Patients After Coronary Stenting: A Comparison of Native Vessel Stent Restenosis Rates in Different Diabetic Subgroups. Heper, Gülüser; Durmaz, Tahir; Murat, S. Namik; Örnek, Ender // Angiology;May/Jun2002, Vol. 53 Issue 3, p287 

    Analyzes the relationship between stent restenosis and microalbuminuria. Risk factors for restenosis on patients with diabetes; Effect of insulin therapy in restenosis rate; Factors predicting the outcome after coronary stent placement in diabetic patients.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics